Enjoy the watch but the short answer was 'No'. Because it's such...

Enjoy the watch but the short answer was 'No'.

Because it's such a minor adjustment to the cell manufacturing process, it's not anticipated that any regulatory submissions will need to be made by companies that wish to incorporate CellPryme into their existing CAR-T programs.

Was a heavy, but fruitful presentation.

My general understanding was, the adjustment to the manufacturing process allows for a change in % of different cell types...By having more helper cells, these will support the tumour attacking cells and allow them to attack solid tumours for longer, vigorously with less fatigue whilst also having better trafficking capabilities to smell out the solid tumours...These helper cells are great at finding the solid tumours which is important given the infusion is into the circulatory system which is fine for blood cancers but with solid the CAR-T therapy will need to exit the blood stream at some stage and locate the solid tumours.

I'm actually more excited for what this manufacturing process will mean for our OmniCAR & it's 3 (different cancer cells) sub CAR-T programs next year, than I am for 3rd party licensing deals.

Very intriguing stuff.

Excellent work Rebecca Lim, but well done to the entire PTX team and also thanks to 'Peter MacCallum' for the support & use of their cutting edge facilities & staff.